Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

The new duvakitug data also clear up the question of whether the hit on the primary endpoint of clinical remission was driven by subgroup performance. Sanofi and Teva saw higher rates of clinical ...

BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing ...

Robert is currently chief digital officer at the cruise line firm Viking Cruises and will join Sanofi on 15th June. His brief is to drive Sanofi’s digital, data and technology strategy ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical companies in order to continue successfully introducing new products in major markets ...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

A global pharmaceutical company, having recently acquired a mid-cap biotech firm, sought to evaluate the market value of a ...

I see it as a big, squiggly E, but the company calls it “The Path.” Eventbrite says The Path is “our dynamic new mark ...